Results 151 to 160 of about 8,420 (208)
Development and Evaluation of a Modified Fixed-Dose Combination Antihypertensive Tablet Containing S-Amlodipine Besylate: A Bioequivalence and Stability Study. [PDF]
Moon HW, Jeong JH, Park CW.
europepmc +1 more source
Antihypertensive drug use for hypertensive disorders of pregnancy in hospitals across nine Chinese cities: a real-world data study. [PDF]
Zhu Z, Tang Y, Lv J, Wang X.
europepmc +1 more source
Olmesartan-Associated Enteropathy With Severe Diarrhoea and Acute Kidney Injury. [PDF]
Nikolaeva A, Della Vecchia A.
europepmc +1 more source
Single-Pill Combination Olmesartan/Amlodipine/Hydrochlorothiazide Safety and Effectiveness in Older Patients with Hypertension: Pooled Analysis of Post-Approval Observational Studies. [PDF]
Kim HJ, Kim HM, Kim DH.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Olmesartan Medoxomil/Amlodipine
Drugs, 2009black triangle Olmesartan medoxomil/amlodipine is a fixed-dose combination of olmesartan medoxomil and amlodipine, both established antihypertensive agents. Dose titration with the individual constituent drugs is recommended before switching to the equivalent fixed-dose combination.
Mark Sanford
exaly +3 more sources
Azilsartan medoxomil is an angiotensin receptor blocker (ARB) being developed for hypertension treatment. To compare this ARB with others in the class, we studied the effects of 2 doses of azilsartan medoxomil, with valsartan 320 mg and ...
William B White +2 more
exaly +2 more sources
Drugs, 2002
Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. In well designed randomised trials, olmesartan medoxomil was significantly more effective than placebo, and at dosages of 10 to 20
Gregory T, Warner, Blair, Jarvis
openaire +2 more sources
Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. In well designed randomised trials, olmesartan medoxomil was significantly more effective than placebo, and at dosages of 10 to 20
Gregory T, Warner, Blair, Jarvis
openaire +2 more sources

